Key facts
- It has raised $2.6M; the latest was Seed Round ($2.6M) in Mar 2025.
- Notable investors include NFX, Not Boring, GreyMatter Capital, PsyMed Ventures, SciFounders — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Sculpta Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Sculpta Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sculpta Bio
Operator of a neurotherapeutics company developing protein sculpting drugs intended to treate brain diseases using protein sculpting drugs. The company offers protein sculpting therapeutics, drugs that change the structure and function of disease-causing proteins in the brain using programmable RNA medicines, enabling customers to safer, more specific and more effective therapies for devastating brain disorders compared to traditional genomic medicines.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 5
- Website
- sculpta.bio/
- Ownership
- Privately Held (backing)
Sculpta Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sculpta Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sculpta Bio in its N-PORT filings yet. We sweep new filings monthly.